Sean Nolan and RA Session II

Less than 3 months af­ter launch, the AveX­is crew’s Taysha rais­es $95M Se­ries B. Is an IPO next?

The old AveX­is team is mov­ing quick­ly in Dal­las.

Three months ago, they launched Taysha with $30 mil­lion in Se­ries A fund­ing and a pipeline of gene ther­a­pies out of UT South­west­ern. Now, they’ve an­nounced an over­sub­scribed $95 mil­lion Se­ries B. And the biotech is de­clin­ing all in­ter­view re­quests on the news, the kind of broad si­lence that can in­di­cate an IPO is in the pipeline.

Biotechs, in­clud­ing those rel­a­tive­ly fresh off launch, have been go­ing pub­lic at a fren­zy since the pan­dem­ic be­gan. In­vestors have showed a will­ing­ness to put up­wards of $200 mil­lion to com­pa­nies that have yet to bring a drug in­to the clin­ic. Still, if Taysha were to go pub­lic in the near fu­ture, it would be per­haps the short­est path from launch to IPO in re­cent biotech mem­o­ry.

Taysha launched in April as the brain­child of for­mer AveX­is CEO Sean Nolan and for­mer AveX­is cor­po­rate strat­e­gy chief RA Ses­sion II, who now serve as Taysha’s chair­man and CEO, re­spec­tive­ly. The idea was to tap in­to a line of AAV9 vec­tor gene ther­a­pies that were be­ing de­vel­oped at UT South­west­ern, par­tic­u­lar­ly from the labs of Steven Gray and Berge Mi­nass­ian. The group al­ready had 50 trans­la­tion­al sci­en­tists at work and a GMP fa­cil­i­ty.

The biotech would take a port­fo­lio ap­proach to gene ther­a­py, akin to the one pur­sued by Bridge­Bio (where Ses­sion had been CBO of gene ther­a­py). They li­censed 15 gene ther­a­pies in epilep­sy, neu­rode­vel­op­ment and neu­rode­gen­er­a­tive dis­or­ders, with an op­tion to li­cense 4 more. The com­pa­ny pur­sued new tech­nolo­gies that can be built on top of AAV9, in­clud­ing bi­cistron­ic plas­mids (a vec­tor with 2 genes in­stead of 1), mi­croR­NA knock­down (a method to in­hib­it the tiny strands of RNA that con­trol gene ex­pres­sion), and re­dos­ing.

When they launched, Taysha said they planned to clin­i­cal stud­ies on a gene ther­a­py for Tay-Sachs dis­ease and then file three more INDs in 2021. De­spite the pan­dem­ic, the com­pa­ny said they are still on track for that plan.

Gene ther­a­py tri­als, of course, can cost a fair bit of cash. And the com­pa­ny said that it hopes to even­tu­al­ly con­struct its own com­mer­cial scale pro­duc­tion site in Dal­las – a prospect that per­haps could come soon­er rather than lat­er.

Ugur Sahin, BioNTech CEO (Bernd von Jutrczenka/dpa via AP Images)

BioN­Tech is spear­head­ing an mR­NA vac­cine de­vel­op­ment pro­gram for malar­ia, with a tech trans­fer planned for Africa

Flush with the success of its mRNA Covid-19 vaccine, BioNTech is now gearing up for one of the biggest challenges in vaccine development — which comes without potential profit.

The German mRNA pioneer says it plans to work on a jab for malaria, then transfer the tech to the African continent, where it will work with partners on developing the manufacturing ops needed to make this and other vaccines.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

How one start­up fore­told the neu­ro­science re­nais­sance af­ter '50 years of shit­show'

In the past couple of years, something curious has happened: Pharma and VC dollars started gushing into neuroscience research.

Biogen’s controversial new Alzheimer’s drug Aduhelm has been approved on the basis of removing amyloid plaque from the brain, but the new neuro-focused pharma and biotechs have much loftier aims. Significantly curbing or even curing the most notorious disorders would prove the Holy Grail for a complex system that has tied the world’s best drug developers in knots for decades.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Why is On­col­o­gy Drug De­vel­op­ment Re­search Late to the Dig­i­tal Bio­mark­ers Game?

During the recent Annual ASCO Meeting, thousands of cancer researchers and clinicians from across the globe joined together virtually to present and discuss the latest findings and breakthroughs in cancer research and care. There were more than 5000+ scientific abstracts presented during this event, yet only a handful involved the use of motion-tracking wearables to collect digital measures relating to activity, sleep, mobility, functional status, and/or quality of life. Although these results were a bit disappointing, they should come as no surprise to those of us in the wearable technology field.

Bob Bradway, Amgen CEO (Scott Eisen/Bloomberg via Getty Images)

Am­gen bel­lies back up to the M&A ta­ble for an­oth­er biotech buy­out, this time with a $2.5B deal for an an­ti­body play­er fo­cused on PS­MA

Five months after Amgen CEO Bob Bradway stepped up to the M&A table and acquired Five Prime for $1.9 billion, following up with the smaller Rodeo acquisition, he’s gone back in for another biotech buyout.

This time around, Amgen is paying $900 million cash while committing up to $1.6 billion in milestones to bag the privately held Teneobio, an antibody drug developer that has expertise in developing new bispecifics and multispecifics. In addition, Amgen cited Teneobio’s “T-cell engager platform, which expands on Amgen’s existing leadership position in bispecific T-cell engagers by providing a differentiated, but complementary, approach to Amgen’s current BiTE platform.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

Art Levinson (Calico)

Google-backed Cal­i­co dou­bles down on an­ti-ag­ing R&D pact with Ab­b­Vie as part­ners ante up $1B, start to de­tail drug tar­gets

Seven years after striking up a major R&D alliance, AbbVie and Google-backed anti-aging specialist Calico are doubling down on their work with a joint, $1 billion commitment to continuing their work together. And they’re also beginning to offer some details on where this project is taking them in the clinic.

According to their statement, each of the two players is putting up $500 million more to keep the labs humming.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

Andrea Pfeifer, AC Immune CEO (AC Immune)

Look­ing to repli­cate Covid-19 suc­cess in neu­ro, BioN­Tech back­ers bet on AC Im­mune and its new­ly-ac­quired Parkin­son's vac­cine

The German billionaires behind BioNTech have found a new vaccine project to back.

Through their family office Athos Service, twin brothers Thomas and Andreas Strüngmann are leading a $25 million private placement into Switzerland’s AC Immune — which concurrently announced that it’s shelling out $58.7 million worth of stock to acquire Affiris’ portfolio of therapies targeting alpha-synuclein, including a vaccine candidate, for Parkinson’s disease.

Rajiv Shukla, Constellation Alpha Holdings

Can­del gets busy IPO week mov­ing with down­sized raise as Ra­jiv Shuk­la's third SPAC goes pub­lic

Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.

In a week that’s expected to see several biotechs price their IPOs, Candel Therapeutics got things kicked off Tuesday with a muted opener.

The company helmed by former GlaxoSmithKline vet Paul Peter Tak made its way to Nasdaq thanks to a $72 million raise, which was downsized by about 15% than originally anticipated, according to Renaissance Capital. Candel priced at $8 per share after initially seeking to launch in the $13 to $15 range.

Busi­ness­es and schools can man­date the use of Covid-19 vac­cines un­der EUAs, DOJ says

As public and private companies stare down the reality of the Delta variant, many are now requiring that their employees or students be vaccinated against Covid-19 prior to attending school or to returning or starting a new job. Claims that such mandates are illegal or cannot be used for vaccines under emergency use authorizations have now been dismissed.

Setting the record straight, the Department of Justice on Monday called the mandates legal in a new memo, even when used for people with vaccines that remain subject to EUAs.

Gerry Brunk (Lumira)

What will Lu­mi­ra Ven­tures do with $220M? Stay out of the com­fort zone and off the beat­en biotech path

Lumira Ventures closed its largest fund on Monday, raking in $220 million to pump into the life sciences — but instead of targeting biotech hubs like San Francisco and Boston, the company is rolling the dice on “underserved geographies” in the US and Canada.

“We find oftentimes companies located in places like Montreal, or Fort Lauderdale, FL, or Kansas City or Phoenix, AZ just have more capital efficiency and better valuations, without having to compromise anything at all in the quality of the innovation and the management talent,” co-founder and managing partner Gerry Brunk told Endpoints News.